University of California San Francisco
Give to UCSF
Brainpower May Take A Beating Following Concussion
Concussion may have a long-term impact on cognition, a new UCSF-led study finds. Fourteen percent of patients had "poor cognitive outcome" one year post injury, with car collisions being the leading cause of concussion.
Global Strategy on Schistosomiasis Gets a Reboot, Based on Research by UCSF Physician
In medical school, Nathan Lo thought we could do more to help the 750 million people around the world with or at risk of getting schistosomiasis. This week, he helped World Health Organization rewrite guidelines to treat everyone in affected communities.
UCSF Is Top Public Recipient of NIH Funding for 15th Year
For the 15th year in a row, UCSF garnered the top spot among public institutions in funding from the National Institutes of Health (NIH) in 2021. UCSF continued to rank highly among all public and private institutions nationwide, ranking fourth overall.
UCSF Gene Therapy for Deadly Mutation Fast-Tracked for FDA Review
A new fast-track review for UCSF gene therapy could help more kids with deadly Artemis-SCID disease get life-saving treatment sooner.
Immune Cells Leave Fingerprints on Tumors Metastasized to the Brain, Offering Clues to Future Therapies
Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types.
UCSF Dyslexia Researchers Develop Tool to Flag Early Reading Challenges
UCSF researchers have developed a digital tool to flag early reading challenges that may lead to dyslexia, and it could be in widespread use in California public schools by 2023. Governor Gavin Newsom is proposing $10 million in the state budget for the project.
Drug Offers New Hope to Select Patients with ALS, UCSF-CPMC Study Shows
A UCSF-led study found a new drug for ALS that shows to slow or temporarily stall the progression of ALS in a select group of patients, with three times as many patients' disease slowing compared to those who received a placebo.
